Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

被引：0
|
作者：
Macaron, Walid
Kantarjian, Hagop M.
Short, Nicholas James
Ravandi, Farhad
Jain, Nitin
Kadia, Tapan M.
Haddad, Fadi
Valero, Yesid Alvarado
Daver, Naval Guastad
Borthakur, Gautam
Dinardo, Courtney Denton
Konopleva, Marina
Wierda, William G.
Jacob, Jovitta
Roy, Edith
Loiselle, Christopher
Milton, Anna
Rivera, Juan
Garris, Rebecca
Jabbour, Elias
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7011
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL)
    Richard-Carpentier, Guillaume
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Schroeder, Heather M.
    Garcia-Manero, Guillermo
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    Kwari, Monica
    Loiselle, Christopher
    Garris, Rebecca
    Volter, Nicole
    Jain, Nitin
    Konopleva, Marina Y.
    Takahashi, Koichi
    Sasaki, Koji
    Wierda, William G.
    Jabbour, Elias
    BLOOD, 2019, 134
  • [42] Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
    Jabbour, Elias J.
    Sasaki, Koji
    Ravandi, Farhad
    Short, Nicholas J.
    Garcia-Manero, Guillermo
    Daver, Naval
    Kadia, Tapan
    Konopleva, Marina
    Jain, Nitin
    Cortes, Jorge
    Issa, Ghayas C.
    Jacob, Jovitta
    Kwari, Monica
    Thompson, Philip
    Garris, Rebecca
    Pemmaraju, Naveen
    Yilmaz, Musa
    O'Brien, Susan M.
    Kantarjian, Hagop M.
    CANCER, 2019, 125 (15) : 2579 - 2586
  • [43] A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
    Nguyen, Daniel
    Jabbour, Elias
    Short, Nicholas
    Issa, Ghayas C.
    Yilmaz, Musa
    Daver, Naval
    Pemmaraju, Naveen
    Chien, Kelly S.
    Masarova, Lucia
    Ravandi, Farhad
    Jain, Nitin
    Deen, Wuliamatu
    Zhao, Min
    Loiselle, Christopher
    Waller, Lourdes
    Banks, Glenda
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 6127 - 6129
  • [44] "Dose-Dense" Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves High Rates of Rapid MRD-Negativity in Patients with Philadelphia Chromosome-Negative B- Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis
    Jamison, Trevor
    Kantarjian, Hagop M.
    Paul, Shilpa
    Cuglievan, Branko
    McCall, David
    Jain, Nitin
    Haddad, Fadi G.
    Marx, Kayleigh R.
    Rausch, Caitlin R.
    Savoy, J. Michael
    Nasr, Lewis
    Nasnas, Cedric
    Zoghbi, Marianne
    Garris, Rebecca
    Ravandi, Farhad
    Konopleva, Marina Y.
    Jabbour, Elias
    Short, Nicholas J.
    BLOOD, 2023, 142
  • [45] Phase II Study of Pedi-Crib: Mini-Hyper-CVD with Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric Patients with B-Cell Lineage Acute Lymphocytic Leukemia
    Mccall, David
    Gibson, Amber
    Garcia, Miriam B.
    Nunez, Cesar
    Roth, Michael E.
    Cuglievan, Branko
    BLOOD, 2024, 144 : 14311 - 14312
  • [46] A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
    Short, Nicholas James
    Jabbour, Elias
    Jain, Nitin
    Macaron, Walid
    Huang, Xuelin
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Daver, Naval Guastad
    Haddad, Fadi
    Zoghbi, Marianne
    Nasnas, Cedric Christophe
    Nasr, Lewis Fady
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Thankachan, Jennifer
    Loiselle, Christopher
    Garris, Rebecca
    Konopleva, Marina
    Ravandi, Farhad
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [47] Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study
    Haddad, Fadi
    Jabbour, Elias
    Short, Nicholas
    Jain, Nitin
    Huante, Emmanuel Almanza
    Sasaki, Koji
    Nasnas, Patrice
    Ravandi, Farhad
    Kebriaei, Partow
    Huang, Xuelin
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Champlin, Richard E.
    Kadia, Tapan M.
    Takahashi, Koichi
    Daver, Naval
    Khoury, Joseph D.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Jacob, Jovitta
    Garris, Rebecca
    Kantarjian, Hagop
    BLOOD, 2022, 140 : 11698 - 11701
  • [48] Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
    Chevallier, Patrice
    Leguay, Thibault
    Kim, Rathana
    Delord, Marc
    Doubek, Michael
    Huguet, Francoise
    Cabannes-Hamy, Aurelie
    Wartiovaara-Kautto, Ulla
    Saillard, Colombe
    Raffoux, Emmanuel
    Cluzeau, Thomas
    Lepretre, Stephane
    Balsat, Marie
    Berceanu, Anna
    Boissel, Nicolas
    Gardin, Claude
    Clappier, Emmanuelle
    Dombret, Herve
    Rousselot, Philippe
    BLOOD, 2022, 140 : 6114 - 6116
  • [49] Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial
    Sasaki, Koji
    Jabbour, Elias J.
    O'Brien, Susan M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Daver, Naval
    Borthakur, Gautam
    Jain, Nitin
    Konopleva, Marina
    Short, Nicholas J.
    Pemmaraju, Naveen
    Alvarado, Yesid
    Jacob, Jovitta
    Garris, Rebecca
    Thompson, Philip A.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    BLOOD, 2016, 128 (22)
  • [50] Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Ashwin, Anand
    Duvall, Adam S.
    Saygin, Caner
    Weiner, Howard
    Dworkin, Emily
    Noorani, Afsheen
    Matthews, Jamie
    Marroquin, Rafael Madero
    Drazer, Michael W.
    Nawas, Mariam T.
    Roloff, Gregory W.
    Kosuri, Satyajit
    Thirman, Michael J.
    Larson, Richard A.
    Odenike, Olatoyosi
    Karrison, Theodore
    Stock, Wendy
    BLOOD, 2024, 144 : 1432 - 1433
12345